Empowered Patient Podcast

Dr. Katherine Iscoe is the Co-Founder and CEO of Advanced Human Imaging. AHI has developed image processing technology for the body, face, and skin along with health-related risk assessment models for their individual healthcare partners. The analysis of these images can identify early warning signs for a wide range of diseases, including determining if a mole on the skin is benign or potentially cancerous.

Katherine explains, "It's big technology in a very small space, that's for sure. We have developed an on-device capturing technology, where we use the phone's camera to capture images of the human body, or it could be the face. And then we take the information that's stored within those images."

"Often, we look at a photograph, and we just think, "That's very pretty." Still, there's so much data within those images, and we use that data to process that information within the device. So that's quite important because the images never leave the device."

"The output of this processing of data is incredibly accurate results. The data can be used to provide biometrics, which is just this fancy word for measurements of the human body. So these could be everything from your waist or your hip circumference, but the combination of these data points can also be used for health risk markers, such as the relationship between your waist and hip. We know that central adiposity is a very strong marker for future metabolic risk, such as syndrome X."

@HumanImaging #HealthTech #FitnessTech #BodyScan #FaceScan #DermaScan #DigitalHealth #MedTech

ahi.tech

Listen to the podcast here

Dr. Katherine Iscoe is the Co-Founder and CEO of Advanced Human Imaging. AHI has developed image processing technology for the body, face, and skin along with health-related risk assessment models for their individual healthcare partners. The analysis of these images can identify early warning signs for a wide range of diseases, including determining if a mole on the skin is benign or potentially cancerous.

Katherine explains, "It's big technology in a very small space, that's for sure. We have developed an on-device capturing technology, where we use the phone's camera to capture images of the human body, or it could be the face. And then we take the information that's stored within those images."

"Often, we look at a photograph, and we just think, "That's very pretty." Still, there's so much data within those images, and we use that data to process that information within the device. So that's quite important because the images never leave the device."

"The output of this processing of data is incredibly accurate results. The data can be used to provide biometrics, which is just this fancy word for measurements of the human body. So these could be everything from your waist or your hip circumference, but the combination of these data points can also be used for health risk markers, such as the relationship between your waist and hip. We know that central adiposity is a very strong marker for future metabolic risk, such as syndrome X."

@HumanImaging #HealthTech #FitnessTech #BodyScan #FaceScan #DermaScan #DigitalHealth #MedTech

ahi.tech

Download the transcript here

Dr. Travis Mickle is the President and CEO of KemPharm, a clinical clinical-stage specialty pharmaceutical company. KemPharm is building on their successful launch of AZSTARYS for ADHD to treat rare sleep disorders like idiopathic hypersomnia as well as sleep disorders that are a symptom of diseases like Alzheimer's and Parkinson's.

Travis explains, "We focused most of our history in the CNS area on a broad base, but idiopathic hypersomnia is now a rare sleep disorder. In the past, we focused on ADHD and pain and larger patient populations. But now, I think, we're focusing more on specific needs of patients with severe, debilitating diseases."

"As an example, our lead product that just got approved last year, AZSTARYS, for ADHD, we thought, well, perhaps it would be better if that product could last longer, as well as have less abuseability."

"That prodrug now makes the basis for our KP1077 for idiopathic hypersomnia. So, you can see how one product can actually have an impact in many different areas when you make a new, improved prodrug form."

@KemPharm #SDX #SleepDisorders #CNS #ADHA #Prodrug #IdiopathicHypersomnia #AZSTARYS #RareDiseases

KemPharm.com

Listen to the podcast here

Dr. Travis Mickle is the President and CEO of KemPharm, a clinical clinical-stage specialty pharmaceutical company. KemPharm is building on their successful launch of AZSTARYS for ADHD to treat rare sleep disorders like idiopathic hypersomnia as well as sleep disorders that are a symptom of diseases like Alzheimer's and Parkinson's.

Travis explains, "We focused most of our history in the CNS area on a broad base, but idiopathic hypersomnia is now a rare sleep disorder. In the past, we focused on ADHD and pain and larger patient populations. But now, I think, we're focusing more on specific needs of patients with severe, debilitating diseases."

"As an example, our lead product that just got approved last year, AZSTARYS, for ADHD, we thought, well, perhaps it would be better if that product could last longer, as well as have less abuseability."

"That prodrug now makes the basis for our KP1077 for idiopathic hypersomnia. So, you can see how one product can actually have an impact in many different areas when you make a new, improved prodrug form."

@KemPharm #SDX #SleepDisorders #CNS #ADHA #Prodrug #IdiopathicHypersomnia #AZSTARYS #RareDiseases

KemPharm.com

Download the transcript here

John Glasspool is the CEO of Anthos Therapeutics, a clinical stage biopharmaceutical company focused on high-risk cardiovascular and metabolic diseases. Anthos is developing innovative therapies for treating thrombosis or more commonly known as clots that are caused by a stroke or heart attack. The current agents, while protecting from a clot, also cause more frequent bleeding. The main unmet need is to give protection from the clots while not having the patient bleed.

John explains, "People that are at risk of these are elderly people who obviously have some changes in the dynamics of their vessels. The other area that's of particular common occurrence is in patients undergoing cancer. And even, in fact, the development of a clot sometimes is the first sign for patients with cancer in their disease prognosis and diagnosis."

"We're developing a factor XI agent. In fact, it's a dual activity factor XI and XIa. What that really means from a patient perspective is we believe that we can pharmacologically uncouple the prevention of your pathological thrombosis, your clot, and yet leave intact your normal hemostasis. If you have a bleed, you clot normally, but we don't increase the bleeding by interfering with normal hemostasis. In our ideal world, and we need to prove this clinically, the drug is still in development, we stop clots while not increasing bleeding."

@Anthos_Tx #Abelacimab #Anticoagulant #Thrombosis #Hemostasis

AnthosTherapeutics.com

Listen to the podcast here

John Glasspool is the CEO of Anthos Therapeutics, a clinical stage biopharmaceutical company focused on high-risk cardiovascular and metabolic diseases. Anthos is developing innovative therapies for treating thrombosis or more commonly known as clots that are caused by a stroke or heart attack. The current agents, while protecting from a clot, also cause more frequent bleeding. The main unmet need is to give protection from the clots while not having the patient bleed.

John explains, "People that are at risk of these are elderly people who obviously have some changes in the dynamics of their vessels. The other area that's of particular common occurrence is in patients undergoing cancer. And even, in fact, the development of a clot sometimes is the first sign for patients with cancer in their disease prognosis and diagnosis."

"We're developing a factor XI agent. In fact, it's a dual activity factor XI and XIa. What that really means from a patient perspective is we believe that we can pharmacologically uncouple the prevention of your pathological thrombosis, your clot, and yet leave intact your normal hemostasis. If you have a bleed, you clot normally, but we don't increase the bleeding by interfering with normal hemostasis. In our ideal world, and we need to prove this clinically, the drug is still in development, we stop clots while not increasing bleeding."

@Anthos_Tx #Abelacimab #Anticoagulant #Thrombosis #Hemostasis

AnthosTherapeutics.com

Download the transcript here

Dr. Robert Foster is the CEO and Founder of Hepion Pharmaceutical which is developing Rencofilstat, a drug in the category of cyclophilin inhibition to target cyclophilins a specific type of enzyme that is present in all humans. These cyclophilins perform a number of functions and are responsible to some extent for the formation of collagen which can lead to events like inflammation and scarring of the liver as well as other liver diseases.

Robert explains, "Liver disease is, unfortunately, way too common. A lot of us are used to eating fatty foods, lots of sugars, processed foods, things like that. It tends to lead to fatty liver disease, which is just way too prevalent. We estimate one in four people globally that have a fatty liver. Then if we let it progress by not losing weight, exercising, and doing all the right things from a dietary standpoint and just a general health standpoint, it can lead to something called NASH.

"NASH is an acronym that stands for non-alcoholic steatohepatitis. Probably about 20% of people with a fatty liver will develop NASH. Within the North American context as well, probably 5% to 10% of the population will have NASH. NASH is one of the leading causes of the development of liver cancer. Unfortunately, it's a little bit too common, and it's a global problem."

"So, there are all these different cyclophilins that do all these different things in terms of driving disease forward. Rencofilstat is a once-a-day oral medication. By giving this medication to people, our hope sincerely is that we can reverse a lot of the things that are leading to this liver disease."

"But together with myself, we have collectively over 100 years of experience only in this class called cyclophilin inhibition. Really, just about all we know is cyclophilin inhibition, and drugs developed around this whole body of knowledge."

@HepionPharma #LiverDisease #Fibrosis #NASH #NonAlcoholicSteatohepatitis #HCC #Cyclophilins #CyclophilinInhibition

HepionPharma.com

Listen to the podcast here

Dr. Robert Foster is the CEO and Founder of Hepion Pharmaceutical which is developing Rencofilstat, a drug in the category of cyclophilin inhibition to target cyclophilins a specific type of enzyme that is present in all humans. These cyclophilins perform a number of functions and are responsible to some extent for the formation of collagen which can lead to events like inflammation and scarring of the liver as well as other liver diseases.

Robert explains, "Liver disease is, unfortunately, way too common. A lot of us are used to eating fatty foods, lots of sugars, processed foods, things like that. It tends to lead to fatty liver disease, which is just way too prevalent. We estimate one in four people globally that have a fatty liver. Then if we let it progress by not losing weight, exercising, and doing all the right things from a dietary standpoint and just a general health standpoint, it can lead to something called NASH.

"NASH is an acronym that stands for non-alcoholic steatohepatitis. Probably about 20% of people with a fatty liver will develop NASH. Within the North American context as well, probably 5% to 10% of the population will have NASH. NASH is one of the leading causes of the development of liver cancer. Unfortunately, it's a little bit too common, and it's a global problem."

"So, there are all these different cyclophilins that do all these different things in terms of driving disease forward. Rencofilstat is a once-a-day oral medication. By giving this medication to people, our hope sincerely is that we can reverse a lot of the things that are leading to this liver disease."

"But together with myself, we have collectively over 100 years of experience only in this class called cyclophilin inhibition. Really, just about all we know is cyclophilin inhibition, and drugs developed around this whole body of knowledge."

@HepionPharma #LiverDisease #Fibrosis #NASH #NonAlcoholicSteatohepatitis #HCC #Cyclophilins #CyclophilinInhibition

HepionPharma.com

Download the transcript here

Dave Rosa is the President and CEO of NeuroOne and an entrepreneur with extensive experience in the medical device industry. NeuroOne is developing and commercializing thin-film high-definition electrode technology that can dramatically improve neurosurgery where typically, multiple surgeries are needed for diagnostic and therapeutic procedures. Using a photolithographic process to print out these circuits is a distinct advantage over the outdated approach to manufacturing electrodes by hand.

Dave elaborates, "Another key piece of what we're looking to accomplish is to really reduce the number of surgeries that a patient has to undergo by combining multiple functions using the same device. So, when I refer to electrode functions, what I'm really talking about is the ability to record electrical activity in the brain, or other areas of the body, stimulate the tissue for therapeutic purposes, or perform an ablation, which is basically destroying problematic tissue that patients would have if they had epilepsy."

"All the commercially available electrodes that are cleared by the FDA are fairly thick and not flexible. That becomes really important, the flexibility and thinness when you're trying to insert these through minimally invasive procedures. So, for example, in the spine, the thinness and flexibility of our device allow you to basically roll it up into a tube and push it through a needle, which is commonly used in back surgery procedures. Or you can create smaller holes in the skull to insert these electrodes, as opposed to having to remove the entire part of the skull."

@N1MTC #Electrodes #ThinFilmElectrodes #ParkinsonsDisease #Neurosurgery #BrainSurgery #Epilepsy #Depression #ChronicBackPain #MedicalDevices

n1mtc.com

Download the transcript here

Dave Rosa is the President and CEO of NeuroOne and an entrepreneur with extensive experience in the medical device industry. NeuroOne is developing and commercializing thin-film high-definition electrode technology that can dramatically improve neurosurgery where typically, multiple surgeries are needed for diagnostic and therapeutic procedures. Using a photolithographic process to print out these circuits is a distinct advantage over the outdated approach to manufacturing electrodes by hand.

Dave elaborates, "Another key piece of what we're looking to accomplish is to really reduce the number of surgeries that a patient has to undergo by combining multiple functions using the same device. So, when I refer to electrode functions, what I'm really talking about is the ability to record electrical activity in the brain, or other areas of the body, stimulate the tissue for therapeutic purposes, or perform an ablation, which is basically destroying problematic tissue that patients would have if they had epilepsy."

"All the commercially available electrodes that are cleared by the FDA are fairly thick and not flexible. That becomes really important, the flexibility and thinness when you're trying to insert these through minimally invasive procedures. So, for example, in the spine, the thinness and flexibility of our device allow you to basically roll it up into a tube and push it through a needle, which is commonly used in back surgery procedures. Or you can create smaller holes in the skull to insert these electrodes, as opposed to having to remove the entire part of the skull."

@N1MTC #Electrodes #ThinFilmElectrodes #ParkinsonsDisease #Neurosurgery #BrainSurgery #Epilepsy #Depression #ChronicBackPain #MedicalDevices

n1mtc.com

Download the transcript here